At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RSPH Invesco S&P 500 Equal Weight Health Care ETF
Pre-Mkt 10-08 08:41:18 EDT
37.00
+0.03
+0.08%
盘前37.00
+0.000.00%
07:40 EDT
High37.27Low36.95Vol539.35K
Open36.96D1 Closing36.97Amplitude0.87%
Mkt Cap883.19MTradable Cap883.19MTotal Shares23.87M
T/O20.02MT/O Rate2.26%Tradable Shares23.87M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Shandong Oriental Ocean's Subsidiary Secures Medical Device Registration Certificate for Water-Soluble Vitamin Assay Kit
Stock News  ·  16:48
Shandong Oriental Ocean's Subsidiary Secures Medical Device Registration Certificate for Water-Soluble Vitamin Assay Kit
Beijing Strong Biotechnologies Secures Medical Device Registration Certificates for Five Products
Stock News  ·  16:27
Beijing Strong Biotechnologies Secures Medical Device Registration Certificates for Five Products
Centinel Spine Reports 42% Revenue Surge and Return to Profit as It Pursues U.S. IPO, Testing Valuations for Innovative Medical Devices
Stock News  ·  14:58
Centinel Spine Reports 42% Revenue Surge and Return to Profit as It Pursues U.S. IPO, Testing Valuations for Innovative Medical Devices
Novartis announces FDA approval of Rhapsido for symptomatic dermographism
TIPRANKS  ·  10-07 23:50
Novartis announces FDA approval of Rhapsido for symptomatic dermographism
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
GlobeNewswire  ·  10-07 23:45
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
Adherium Secures Non-Dilutive AUD$700,000 Loan to Support Working Capital
TIPRANKS  ·  10-07 05:59
Adherium Secures Non-Dilutive AUD$700,000 Loan to Support Working Capital
Press Release: Celcuity Appoints David Gryska to Its Board of Directors
Dow Jones  ·  10-02
Press Release: Celcuity Appoints David Gryska to Its Board of Directors
Abogen announces licensing, option agreement with Novartis
TIPRANKS  ·  10-02
Abogen announces licensing, option agreement with Novartis
Nanobiotix taps veteran biotech CFO Arnd Christ to steer next growth phase
TIPRANKS  ·  10-02
Nanobiotix taps veteran biotech CFO Arnd Christ to steer next growth phase
Oxford BioDynamics Extends Vulpes Payment Deadline in £9.15m Placing
TIPRANKS  ·  10-01
Oxford BioDynamics Extends Vulpes Payment Deadline in £9.15m Placing
Outlook submits HCPCS Level II application to CMS for J-code for LYTENAVA
TIPRANKS  ·  10-01
Outlook submits HCPCS Level II application to CMS for J-code for LYTENAVA
Paramount Names Kreiz as Co-CEO as Warner Bros. Deal Nears Completion
Deep News  ·  10-01
Paramount Names Kreiz as Co-CEO as Warner Bros. Deal Nears Completion
Lantheus announces CMS granted TPT payment status for PYLARIFY TruVu injection
TIPRANKS  ·  09-30
Lantheus announces CMS granted TPT payment status for PYLARIFY TruVu injection
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
GlobeNewswire  ·  09-30
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
2026 Nobel Prize Preview: Scientists Behind GLP-1 Weight-Loss Drugs Emerge as Leading Contenders
Deep News  ·  09-30
2026 Nobel Prize Preview: Scientists Behind GLP-1 Weight-Loss Drugs Emerge as Leading Contenders
Lonza Strengthens Board with Nomination of Biotech Veteran Pearl Huang
TIPRANKS  ·  09-30
Lonza Strengthens Board with Nomination of Biotech Veteran Pearl Huang
Actinogen Medical Adds Modest Number of New Shares to ASX Listing
TIPRANKS  ·  09-30
Actinogen Medical Adds Modest Number of New Shares to ASX Listing
Marvel Biosciences Raises $1.6 Million to Advance Lead Neurology Drug Into Phase 1 Trials
TIPRANKS  ·  09-30
Marvel Biosciences Raises $1.6 Million to Advance Lead Neurology Drug Into Phase 1 Trials
Shenzhen Lifotronic Technology Secures Medical Device Registration Certificate for Photon Therapeutic Apparatus
Stock News  ·  09-29
Shenzhen Lifotronic Technology Secures Medical Device Registration Certificate for Photon Therapeutic Apparatus
Rhythm Biosciences Files Updated Corporate Governance Statement With ASX
TIPRANKS  ·  09-29
Rhythm Biosciences Files Updated Corporate Governance Statement With ASX

Introduction

Company Name.
Invesco S&P 500 Equal Weight Health Care ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index is composed of all of the components of the S&P 500® Health Care Index (the “parent index”). The parent index is designed to measure the performance of common stocks of all companies included in the S&P 500® Index that are classified as members of the health care sector, as defined according to the Global Industry Classification Standard (“GICS®”).
Issue price:
--